Acorda Therapeutics Reports Third Quarter 2023 Financial Results
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
- 11/13/2023
|
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
- 11/06/2023
|
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
- 08/08/2023
|
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
- 08/02/2023
|
Tom Burns Elected to the Acorda Therapeutics Board of Directors
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
- 06/28/2023
|
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
- 06/26/2023
|
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
- 06/26/2023
|
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
- 06/02/2023
|
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.
- 05/31/2023
|
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.
- 05/30/2023
|
Acorda Therapeutics Reports First Quarter 2023 Financial Results
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2023. “We were very pleased to see INBRIJA’s strong performance in the quarter, with U.S. net revenue up by 52% over the same quarter of 2022. In addition, new prescription request forms increased 45% over the first quarter of 2022,” said Ron Cohen, M.D., Acorda’s President and Chief Executive Officer. “We believe that our new marketing programs are having an impact. In April, we launched an INBRIJA television commercial on approximately 50 streaming services, accompanied by a digital ‘surround sound’ campaign to encourage viewers to take an action after viewing the commercial, such as connecting with a nurse educator or speaking to their physician. The initial response has been highly encouraging; in the first six weeks, the commercial has been viewed over 2.5 million times and is already driving substantial traffic to the INBRIJA website.” “Our agreement with Chance Pharmaceuticals is an important step in bringing INBRIJA to those living with Parkinson’s in China; by 2030, it is estimated there will be approximately 5 million people with Parkinson’s disease in that country,” Dr. Cohen continued. “We are also very pleased that Tom Burns, who has decades of finance and accounting experience in biotech and high tech, will stand for election to Acorda’s board in June; we are deeply grateful to Jeff Randall for his superb contributions to the Company since joining the Board in 2006, and we wish him the very best.” First Quarter 2023 Financial Results For the quarter ended March 31, 2023, the Company reported INBRIJA worldwide net revenue of $6.1 million, of which $5.6 million was derived from sales in the U.S., a 52.2% increase compared to the same quarter in 2022. The Company also reported ex-U.S. INBRIJA net revenue of $0.5 million in the first quarter related to the recent launch in Spain in February. For the quarter ended March 31, 2023, the Company reported AMPYRA net revenue of $12.6 million, a 15.4% decrease compared to $14.9 million for the same quarter in 2022. Additionally, for the quarter ended March 31, 2023, the Company reported FAMPYRA royalty revenues of $2.9 million, a 9.3% decrease compared to the same quarter in 2022. As previously disclosed, AMPYRA lost its exclusivity when generics entered the market in 2018, and the Company expects AMPYRA revenue to continue to decline. Research and development (R&D) expenses for the quarter ended March 31, 2023 were $1.4 million, compared to $1.7 million for the same quarter in 2022. Sales, general and administrative (SG&A) expenses for the quarter ended March 31, 2023 were $22.5 million, compared to $26.9 million for the same quarter in 2022. Non-GAAP adjusted operating expenses (adjusted OPEX) for the quarter ended March 31, 2023 was $23.9 million, compared to $28.6 million for the same quarter in 2022. This quarterly non-GAAP measure, more fully described below under “Non-GAAP Financial Measures,” excludes costs of goods sold, amortization of intangible assets, change in fair value of derivative liability, and change in fair value of acquired contingent liability. A reconciliation of the GAAP operating expenses to non-GAAP operating expenses is included with the attached financial statements. Benefit from income taxes for the quarter ended March 31, 2023 was $2 million, compared to a provision for income taxes of $0.3 million for the same quarter in 2022. The Company reported a net loss of ($16.8) million for the quarter ended March 31, 2023, or a net loss of ($0.69) per share on both a basic and diluted basis. Net loss in the same quarter of 2022 was ($24.5) million, or a net loss of ($1.85) per share on both a basic and diluted basis. At March 31, 2023, the Company had cash, cash equivalents, and restricted cash of $37.8 million, compared to $44.7 million at year end 2022. Restricted cash includes $6.2 million in escrow related to the semi-annual interest payment to the holders of its 6.00% convertible senior secured notes (Convertible Notes). 2023 Financial Guidance For the full year 2023, Acorda continues to target INBRIJA U.S. net revenue to be $38 - $42 million, AMPYRA net revenue to be $65 - $70 million, adjusted OPEX to be $93 - $103 million, and ending cash balance to be $43 - $47 million. INBRIJA Commercialization Agreement in China Under the terms of the agreement, Acorda will receive an up-front payment of $2.5 million, a near term milestone payment of up to $6 million, $3 million upon regulatory approval, up to $132.5 million in sales milestones, and a fixed fee for each carton of INBRIJA supplied to Chance. By 2030, it is estimated that China will have approximately 5 million people with Parkinson’s disease due to its aging population1. Chance plans to seek marketing authorization as quickly as possible. Board of Directors Jeff Randall, who has served on Acorda’s Board since 2006, and currently serves as Chair of the Audit Committee, will be rotating off the Board as of the Company’s June 2023 annual meeting of stockholders. Tom Burns, the Senior Vice President of Finance and Chief Financial Officer of XOMA Corporation, will stand for election to the Board at that meeting. Tom is responsible for all financial matters affecting or involving the XOMA companies, including directing XOMA's financial strategy, accounting, budgeting, financial planning and analysis, and investor relations functions. Mr. Burns has 25 years of experience in accounting and finance in both biotechnology and high technology companies. Annual Meeting of Stockholders Acorda’s Annual Meeting of Stockholders will take place on Thursday, June 22, 2023 at 9:00am ET. Stockholders are encouraged to vote by internet, telephone, mail, or in person as described in the materials sent to them so that all shares will be represented at the Annual Meeting. Webcast and Conference Call To participate in the Webcast, please use the following registration link: https://events.q4inc.com/attendee/539980595 If you register for the Webcast, you will have the opportunity to submit a written question for the Q&A portion of the presentation. After you have registered, you will receive a confirmation email with the Webcast details. On the day of the Webcast, you will receive an email 2 hours prior to the start of the Webcast with the link to join. The presentation will be available on the Investors section of www.acorda.com. A replay of the call will be available from 8:30 p.m. ET on May 11, 2023 until 11:59 p.m. ET on June 10, 2023. To access the replay, please dial 1 866 813 9403 (domestic) or +44 204 525 0658 (international); access code 270385. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Non-GAAP Financial Measures This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP) and also certain historical and forward-looking non-GAAP financial measures. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP, and the calculation of the non-GAAP financial measures included herein may differ from similarly titled measures used by other companies. The Company believes that the presentation of these non-GAAP financial measures, when viewed in conjunction with actual GAAP results, provides investors with a more meaningful understanding of our ongoing and projected operating performance because it excludes (i) expenses that pertain to corporate restructurings not routine to the operation of our business, (ii) non-cash charges that are substantially dependent on changes in the market price of our common stock, and (iii) other items as set forth above that are not ascertainable at the present time. We believe these non-GAAP financial measures help indicate underlying trends in the Company’s business and are important in comparing current results with prior period results and understanding expected operating performance. Also, management uses these non-GAAP financial measures to establish budgets and operational goals, and to manage the Company’s business and evaluate its performance. In addition, management believes that adjusted OPEX is important in evaluating the administrative costs of operating the Company’s business. Adjusted OPEX includes (i) research and development expenses and (ii) selling, general, and administrative expenses, and excludes (i) costs of goods sold, (ii) amortization of intangible assets, (iii) change in fair value of derivative liability, and (iv) change in fair value of acquired contingent liability. We are unable to reconcile our guidance for this non-GAAP measure to GAAP due to the forward-looking nature of the adjustments that are needed to determine this information, which includes information regarding future compensation charges, future changes in the market price of our common stock, and changes in the fair value of derivative and contingent liabilities, none of which are available at this time. About Acorda Therapeutics Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. INBRIJA utilizes Acorda’s innovative ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Acorda also markets the branded AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg. Forward-Looking Statements This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: we may not be able to successfully market INBRIJA, AMPYRA or any other products under development; the COVID-19 pandemic, including related restrictions on in-person interactions and travel, and the potential for illness, quarantines and vaccine mandates affecting our management, employees or consultants or those that work for other companies we rely upon, could have a material adverse effect on our business operations or product sales; our ability to attract and retain key management and other personnel, or maintain access to expert advisors; our ability to raise additional funds to finance our operations, repay outstanding indebtedness or satisfy other obligations, and our ability to control our costs or reduce planned expenditures; risks associated with the trading of our common stock; risks related to the successful implementation of our business plan, including the accuracy of its key assumptions; risks related to our corporate restructurings, including our ability to outsource certain operations, realize expected cost savings and maintain the workforce needed for continued operations; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of INBRIJA or AMPYRA to meet market demand; our reliance on third-party manufacturers for the timely production of commercial supplies of INBRIJA and AMPYRA; third-party payers (including governmental agencies) may not reimburse for the use of INBRIJA or AMPYRA at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; reliance on collaborators and distributors to commercialize INBRIJA and AMPYRA outside the U.S.; our ability to satisfy our obligations to distributors and collaboration partners outside the U.S. relating to commercialization and supply of INBRIJA and AMPYRA; competition for INBRIJA and AMPYRA, including increasing competition and accompanying loss of revenues in the U.S. from generic versions of AMPYRA (dalfampridine) following our loss of patent exclusivity; the ability to realize the benefits anticipated from acquisitions because, among other reasons, acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; the risk of unfavorable results from future studies of INBRIJA (levodopa inhalation powder) or from other research and development programs, or any other acquired or in-licensed programs; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class-action litigation; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third-party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies. These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release, except as may be required by law. Financial Statements Acorda Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) March 31, December 31, 2023 2022 (unaudited) Assets Cash and cash equivalents $ 30,255 $ 37,536 Restricted cash - short term 6,989 6,884 Trade receivable, net 9,190 13,866 Other current assets 8,195 11,077 Inventories, net 13,465 12,752 Property and equipment, net 2,383 2,603 Intangible assets, net 297,393 305,086 Restricted cash - long term 510 255 Right of use assets, net 5,029 5,287 Other assets 1,497 247 Total assets $ 374,906 $ 395,595 Liabilities and stockholders' equity Accounts payable, accrued expenses and other current liabilities $ 29,871 $ 33,872 Current portion of lease liability 1,556 1,545 Current portion of royalty liability — — Current portion of contingent consideration 3,312 2,532 Convertible senior notes 171,496 167,031 Derivative liability related to conversion option — - Non-current portion of acquired contingent consideration 36,488 38,668 Non-current portion of lease liability 4,055 4,341 Non-current portion of loans payable - — Deferred tax liability 41,805 44,202 Other long-term liabilities 9,363 9,780 Total stockholders' equity 76,960 93,622 Total liabilities and stockholders' equity $ 374,906 $ 395,595 Acorda Therapeutics, Inc. Consolidated Statements of Operations (in thousands, except per share amounts) (unaudited) Three Months Ended March 31, 2023 2022 Revenues: Net product revenues $ 18,719 $ 18,575 Royalty revenues 3,528 3,959 License revenue 11 - Total revenues 22,258 22,534 Costs and expenses: Cost of sales 3,234 5,967 Research and development 1,386 1,694 Selling, general and administrative 22,514 26,938 Amortization of intangible assets 7,691 7,691 Change in fair value of derivative liability — (30 ) Change in fair value of acquired contingent consideration (1,091 ) (3,023 ) Other operating expense, net - - Total operating expenses 33,734 39,237 Operating income (loss) $ (11,476 ) $ (16,703 ) Other income (expense), net: Interest expense, net (7,477 ) (7,561 ) Other income (expense), net 91 - Total other income (expense), net (7,386 ) (7,561 ) Income (loss) before income taxes (18,862 ) (24,264 ) (Provision for) benefit from income taxes 2,038 (258 ) Net income (loss) $ (16,824 ) $ (24,522 ) Net income (loss) per common share - basic $ (0.69 ) $ (1.85 ) Net income (loss) per common share - diluted $ (0.69 ) $ (1.85 ) Weighted average common shares - basic 24,338 13,251 Weighted average common shares - diluted 24,338 13,251 Acorda Therapeutics, Inc. Adjusted Operating Expenses Reconciliation (in thousands, except per share amounts) (unaudited) Three Months Ended Three Months Ended March 31, March 31, 2023 2022 Operating Expenses per Income Statement (GAAP) $ 33,734 $ 39,237 Adjustments: Cost of goods sold (3,234 ) (5,967 ) Amortization of intangible assets (7,691 ) (7,691 ) Change in fair value of derivative liability - 30 Change in fair value of acquired contingent consideration 1,091 3,023 Total adjustments (9,834 ) (10,605 ) Adjusted operating expenses (non-GAAP) $ 23,900 $ 28,632 1Li, G., Ma, J., Cui, S. et al. Parkinson’s disease in China: a forty-year growing track of bedside work. Transl Neurodegener 8, 22 (2019). https://doi.org/10.1186/s40035-019-0162-z
- 05/11/2023
|
3 Penny Stocks to Avoid as Interest Rates Rise in 2023
- Prudent investors are now forced to reassess their portfolios and risk profiles. Indeed, for those invested in penny stocks, the promise of substantial returns is great.
- 05/11/2023
|
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
- PEARL RIVER, N.Y.
- 03/06/2023
|
Acorda Therapeutics, Inc. (ACOR) Q3 2022 Earnings Call Transcript
- Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Welcome to Acorda Therapeutics' Third Quarter 2022 Financial and Business Update.
- 11/01/2022
|
Acorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting
- Acorda Therapeutics Inc (NASDAQ:ACOR) has provided long-term financial guidance and an updated business plan in preparation for the special meeting of its stockholders this week, and updated its net revenue forecast from US$116 million to $121 million in 2023, and as much as $199 million by 2027. The Pearl River, New York-based company said it expects to increase the market for two of its pharmaceuticals – Inbrija for patients with Parkinson's disease, and Ampyra, used to treat adults with multiple sclerosis.
- 10/31/2022
|
Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
- PEARL RIVER, N.Y.
- 10/25/2022
|
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
- Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
- 10/24/2022
|
How to Find Penny Stocks to Buy Right Now
- Use these tricks for finding penny stocks to buy this week The post How to Find Penny Stocks to Buy Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/18/2022
|
Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
- PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
- 09/08/2022
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2022 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - CEO Mike Gesser - CFO Operator Ladies and gentlemen, welcome to Acorda Therapeutics' Second Quarter 2022 Financial and Business Update. [Operator Instructions] Please be advised that this call is being recorded at the company's request.
- 08/07/2022
|
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
- 07/28/2022
|
Best Penny Stocks to Watch as the Market Crashes Again
- Here are three penny stocks to add to your watchlist right now The post Best Penny Stocks to Watch as the Market Crashes Again appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/16/2022
|
Why Acorda Therapeutics Shares Gaining Today?
- Acorda Therapeutics Inc (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episodes) in.
- 06/16/2022
|
What to Know About Buying Penny Stocks on June 6th
- Here's what you need to know about trading penny stocks on June 6th, 2022 The post What to Know About Buying Penny Stocks on June 6th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/06/2022
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2022 Results - Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 5:02 PM ET Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q1 2022 Earnings Conference Call May 11, 2022, 16:30 PM ET Company Participants Ron Cohen - Founder, President and CEO Mike Gesser - CFO Tierney Saccavino - EVP, Corporate Communications Conference Call Participants Muzamil Saleem - H.C. Wainwright Operator Good afternoon.
- 05/11/2022
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2021 Results - Earnings Call Transcript
- 03/09/2022
|
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
- 02/24/2022
|
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
- 01/04/2022
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2021 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes
- 09/09/2021
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2021 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results
- 08/05/2021
|
Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
- 07/30/2021
|
Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know
- Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2021
|
Acorda Therapeutics Continues To Maneuver For A Turnaround
- Acorda Therapeutics Continues To Maneuver For A Turnaround
- 07/24/2021
|
ACOR Stock Increases Over 40% Pre-Market: Why It Happened
- The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) increased by over 40% pre-market. This is why it happened.
- 07/23/2021
|
Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med
- Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.
- 07/23/2021
|
ACOR Stock Increased 24.67% After Hours: Why It Happened
- The stock price of Acorda Therapeutics Inc (NASDAQ: ACOR) increased 24.67% after hours. This is why it happened.
- 07/23/2021
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q1 2021 Results - Earnings Call Transcript
- 05/09/2021
|
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
- Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/06/2021
|
Acorda Therapeutics: Buying Before The Coast Is Clear
- Acorda Therapeutics: Buying Before The Coast Is Clear
- 04/29/2021
|
Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics First Quarter 2021 Update: Webcast/Conference Call Scheduled for May 6, 2021
- 04/29/2021
|
Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?
- Is (ACOR) Outperforming Other Medical Stocks This Year?
- 03/10/2021
|
Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at H.C. Wainwright Global Life Sciences Virtual Conference
- 03/08/2021
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q4 2020 Results - Earnings Call Transcript
- 03/04/2021
|
Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates
- Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/04/2021
|
Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2020 Update: Webcast/Conference Call Scheduled for March 4, 2021
- 02/25/2021
|
Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?
- Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.
- 02/24/2021
|
Acorda (ACOR) to Report Q4 Earnings: What's in the Cards?
- During Acorda's (ACOR) upcoming Q4 earnings call, investor focus will be on the sales uptake of its Parkinson's disease drug, Inbrija.
- 02/08/2021
|
Acorda (ACOR) Soars on Sale of Manufacturing Unit for Inbrija
- Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs.
- 01/14/2021
|
Acorda Therapeutics Announces Agreement for Sale of Manufacturing Operations and Long-Term Global Supply Agreement for INBRIJA®, Corporate Restructuring, and Enters into “At The Market” Offering Agreement
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda's patients and continued adheren
- 01/13/2021
|
Acorda Therapeutics to Present at 39th Annual J.P. Morgan Health Care Conference
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Health Care Conference on Thursday, January 14, at 5:20 PM ET. A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com. An archived version of the webcast will be available following the presentation. About Acorda Therapeu
- 01/12/2021
|
Acorda Therapeutics to Present at H.C. Wainwright BIOCONNECT Virtual Conference
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., President and Chief Executive Officer, will present during the January 11th -14th H.C. Wainwright BIOCONNECT Virtual Conference. An audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com. For more information about the conference, please visit the event website at www.hcwevents.com/bioconnect. About Acorda The
- 01/11/2021
|
Acorda Therapeutics Announces Completion of One-for-Six Reverse Stock Split
- ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the previously announced 1-for-6 reverse stock split of its outstanding and authorized shares of common stock. The reverse stock split became effective at 4:01 p.m. Eastern Time today, and the Company's common stock will begin trading on a split-adjusted basis at the market open on January 4, 2021. The reverse stock split was effected in accordance with the authorization adopted by Aco
- 12/31/2020
|
Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript
- Acorda Therapeutics, Inc. (ACOR) CEO Ron Cohen on Q3 2020 Results - Earnings Call Transcript
- 11/03/2020
|
Acorda Therapeutics: Q3 Earnings Insights
- Shares of Acorda Therapeutics (NASDAQ:ACOR) increased 8.33% after the company reported Q3 results. Quarterly Results Earnings per share rose 50.00% over the past year to ($0.23), which beat the estimate of ($0.31).
- 11/03/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform
- Perceptive Advisors launches LianBio with multiple strategic alliances to develop and commercialize therapeutics in China and major Asian markets.
- 08/11/2020
|
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
- Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both compa
- 08/10/2020
|
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
- Bayer announced today that the United States Food and Drug Administration (FDA) has approved Lampit® (nifurtimox) for use in pediatric patients (from
- 08/07/2020
|
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
- Acorda (ACOR) delivered earnings and revenue surprises of 23.91% and 27.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2020
|
Acorda Therapeutics: Q2 Earnings Insights
- Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 20% after the company reported Q2 results.Quarterly Results Earnings per share rose 36.36% year over year to ($0.35), which beat the estimate of ($0.48).Revenue of $33,617,000 decreased by 32.84% from the same period last year, which beat the estimate of $27,500,000.Outlook Earnings guidance hasn't been issued by the company for now.Acorda Therapeutics hasn't issued any revenue guidance for the time being.Conference Call Details Date: Aug 04, 2020View more earnings on ACORTime: 04:30 PMET Webcast URL: https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&referrer=https%3A%2F%2Fpro.benzinga.com%2Fdashboard%2F&eventid=2395726&sessionid=1&key=EF22DB54EC8EDBD04D72B50A619971E1®Tag=&sourcepage=registerPrice Action 52-week high: $5.5652-week low: $0.60Price action over last quarter: down 24.40%Company Profile Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.See more from Benzinga * Stocks That Hit 52-Week Lows On Thursday * 20 Healthcare Stocks Moving In Wednesday's Pre-Market Session * Stocks That Hit 52-Week Lows On Tuesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/04/2020
|
Acorda Reports Second Quarter 2020 Financial Results
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the second quarter ended June 30, 2020.
- 08/04/2020
|
FDA Issues Emergency Use Authorization for Impella Heart Pumps to Provide Unloading Therapy to COVID-19 Patients
- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for left-sided Impella heart pumps to provide lef
- 08/04/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders
- Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on July 31, 2020, and stockholders approved proposals to authorize the Company’s Board of Directors to implement a reverse stock split, and to adjourn the meeting to provide stockholders with additional time to vote on Proposal One to approve an increase to the number of authorized shares of common stock. The Special Meeting will be reconvened on Friday, August 28, 2020 at 9:00 a.m. Eastern Time at the Company’s principal executive office located at 420 Saw Mill River Road, Ardsley, NY 10502. The sole matter of business before the reconvened Special Meeting will be Proposal One.
- 07/31/2020
|
Best Chance Products Emerges as a Key Player in the US Personal Protective Equipment Market, Named Exclusive Distributor for BioCore nCoV-19 Real Time PCR Kits
- Best Chance Products, LLC, a distribution and sales company providing a supply chain of personal protective equipment, has been named the exclusive di
- 07/31/2020
|
Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its second quarter 2020 update and financial results on Tuesday, August 4 at 4:30 p.m. ET.
- 07/28/2020
|
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)
Altimmune Inc (NASDAQ: ALT...
- 07/15/2020
|
Cipla gets USFDA nod for rare genetic condition treatment drug
- Cipla's Icatibant injectable pre-filled syringe in the strength of 30mg/3mL is generic version of Shire's Firazyr, the company said in a regulatory filing.
- 07/14/2020
|
Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)?
- How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
- 07/08/2020
|
Nemaura Medical Submits PMA Application for sugarBEAT® to U.S. FDA
- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable dia
- 07/07/2020
|
Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial
- The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) to treat COVID-19 patients.
- 07/06/2020
|
AMGN Stock Jumped 8%, Amgen Beats Novartis in Patent Battle
- U.S.-based pharmaceutical giant Amgen wins Appeal Court ruling upholding the patent of its drug Enbrel, Amgen (AMGN) stock is up.
- 07/02/2020
|
Global Butylated Hydroxytoluene Market Growth, Trends and Outlook to 2025 - Unfavorable Conditions Arising from the Outbreak of COVID-19 Hindering Market Growth - ResearchAndMarkets.com
|
Cidade da Fl
- A cidade da Fl
- 06/30/2020
|
Cidade da Fl
- A cidade da Fl
- 06/29/2020
|
ABMC Reports Fourth Quarter and Year End 2019 Results | | IT Business Net
- KINDERHOOK, NY / ACCESSWIRE / June 26, 2019 / American Bio Medica Corporation (OTC PINK:ABMC) today announced financial results for the fourth quarter and year ended December 31, 2019. Chief Executive
- 06/26/2020
|
Maharashtra and Delhi among States to Get First Set of Covid-19 Drug Covifor from Hetero
- The company said it has fixed a maximum retail price of Rs 5,400 per vial for the drug.
- 06/25/2020
|
Maharashtra, Delhi among 5 states to receive first batch of COVID-19 drug
- Hetero Healthcare is set to deliver the first batch of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, and Maharashtra.
- 06/25/2020
|
Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across India
- The company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, Hetero Healthcare said in a statement.
- 06/24/2020
|
Explained: The various drugs being used for treating Covid-19 symptoms in India now
- Coronavirus (Covid-19) Medicine Latest Update: Companies have launched generic versions of Remdesivir and Favipiravir to aid in the treatment of Covid-19, in specific cases, while UK has authorised the use of steroid dexamethasone.
- 06/24/2020
|
Hetero Set to Supply 20,00 Vials of Covifor at Rs 5,400 Each for Covid-19 Treatment
- One set would be immediately supplied to Hyderabad, Delhi, Gujarat, Tamil Nadu, Mumbai and other parts of Maharashtra, a press release from the city-based drug-maker said.
- 06/24/2020
|
Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across India
|
Cipremi: Cipla to price remdesivir version for COVID-19 drug under Rs 5,000
- Mumbai-based drugmaker Cipla on Tuesday announced that it will price 'Cipremi', its generic version of Gilead Sciences Inc's antiviral drug remdesivir for use in Covid-19 patients, at less than ₹5,000 ($66) per 100mg vial.
- 06/24/2020
|
Zydus Cadila gets USFDA nod to market generic antihistamine tablets
- The drug will be manufactured at the group's manufacturing facility in Ahmedabad
- 06/24/2020
|
COVID-19 drug: Cipla to price generic version of remdesivir below Rs 5,000 per vial, to be available in 8-10 days
- Hyderabad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose.
- 06/23/2020
|
Concerns vapers will take up smoking if proposal to ban liquid nicotine goes ahead
- Around 2,000 small businesses are at risk and 300,000 vapers could potentially return to cigarette smoking, advocates say, if the Health Minister's proposal to ban liquid nicotine imports is approved.
- 06/23/2020
|
Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial
- Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
- 06/23/2020
|
Cipla to price Covid-19 drug remdesivir at less than Rs 5,000 per vial
- Hyderbad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose
- 06/23/2020
|
Cipla to price generic version of COVID-19 drug remdesivir at less than Rs 5,000 per vial
|
Coronavirus Update: FDA Warns These Sanitizers Contain Potentially Fatal Toxic Chemical
- During this health crisis, some companies sought the use of alternative sanitation ingredients like ethanol, isopropanol and methanol in making hand sanitizers.
- 06/23/2020
|
KARYOPHARM THERAPEUTICS INC. : Other Events, Financial Statements and Exhibits (form 8-K) | MarketScreener
|
Cipla hits 52-wk high on launch of generic remdesivir for Covid-19 patients
- Remdesivir is the only USFDA approved emergency use authorization treatment in severe (hospitalised) Covid-19 patients.
- 06/22/2020
|
Bank of New York Mellon Corp Trims Holdings in Acorda Therapeutics Inc (NASDAQ:ACOR)
- Bank of New York Mellon Corp decreased its stake in shares of Acorda Therapeutics Inc (NASDAQ:ACOR) by 2.2% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 529,271 shares of the biopharmaceutical company’s stock after selling 12,036 shares during the quarter. Bank of New […]
- 06/22/2020
|
Hetero gets DCGI nod to launch coronavirus drug, to be priced around Rs 5000 per vial
- Hetero's generic version of Remdesivir will be marketed under the brand name 'Covifor' in India. The drug will be priced at around Rs 5,000 per dose.
- 06/21/2020
|
Hetero gets DCGI nod to launch COVID-19 drug
- Domestic pharma firm Glenmark Pharmaceuticals had on Saturday launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet Hetero has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of COVID-19, it said in a statement.
- 06/21/2020
|
Hetero gets DCGI nod to launch COVID-19 drug
- Drug firm Hetero on Sunday said it has received approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the treatment of COVID-19.The company has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of COVID-19, it said in a statement.
- 06/21/2020
|
Russians eat burgers in gloves - should everyone?
- MOSCOW (NYTIMES) - When you enter a home in Moscow, you take off your shoes. When you go to a play, you have to check your coat. When you eat a burger, you often wear gloves.. Read more at straitstimes.com.
- 06/21/2020
|
Federated Hermes Inc. Acquires 122,111 Shares of Acorda Therapeutics Inc (NASDAQ:ACOR)
- Federated Hermes Inc. raised its holdings in Acorda Therapeutics Inc (NASDAQ:ACOR) by 36.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,905 shares of the biopharmaceutical company’s stock after purchasing an additional 122,111 shares during the quarter. Federated Hermes Inc.’s holdings in […]
- 06/20/2020
|
Dr Reddy's launches generic prostate cancer treatment drug in US
- Pharma major Dr Reddy's Laboratories on Friday said it has launched generic Abiraterone Acetate tablets, used for treatment of prostate cancer, in the US market.
- 06/19/2020
|
Cadila Healthcare's Q4 PBT falls 14% to Rs 522 cr, total income rises 0.66%
- Cadila has also been working on a DNA vaccine to fight Covid-19, which is currently in the animal testing stage
- 06/19/2020
|
Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules
- "Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.
- 06/19/2020
|
Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis
- The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis
- 06/19/2020
|
Glenmark gets final USFDA approval for Fingolimod capsules
- Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA
- 06/19/2020
|
Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules
- Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.
- 06/19/2020
|
Finally, WHO stops chloroquine trial - TheCable
- The World Health Organisation (WHO) says it is stopping hydroxychloroquine solidarity trial for the treatment of COVID-19 patients. This comes three days after the United States Food and Drug Administration (FDA) withdrew
- 06/18/2020
|
Acorda Therapeutics Inc (NASDAQ:ACOR) Shares Purchased by Massachusetts Financial Services Co. MA
- Massachusetts Financial Services Co. MA raised its stake in shares of Acorda Therapeutics Inc (NASDAQ:ACOR) by 18.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,418 shares of the biopharmaceutical company’s stock after purchasing an additional 43,589 shares […]
- 06/18/2020
|
WARNING: Injectable Drugs by Homeopaths May Contain Lead and Mercury
- The FDA has identified four manufacturers labeled as homeopaths that are distributing dangerous injectable drugs.
- 06/18/2020
|
FDA Sued For Inaction Protecting African Americans' Lives - ValueWalk
- Our mission is to save the 45,000 African Americans lives lost each year from tobacco-induced diseases and we have resolutely
- 06/17/2020
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Acorda Therapeutics, Inc. - ACOR
- New York, New York--(Newsfile Corp. - June 16, 2020) - Levi & Korsinsky has commenced an investigation of Acorda Therapeutics, Inc. (NASDAQ: ACOR) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/acorda-therapeutics-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and ...
- 06/16/2020
|
Brazil’s Treasury Secretary departure rattles country’s economic team | Texto em inglês com áudio
- June 16th, 2020. Good evening. Brazilian National Treasury secretary, Mansueto Almeida, has decided to resign from government within the next few weeks. Almeida, who had occupied the position since April 2018, stated he wished to help in the transition process for his successor. Meanwhile, the country’s Education minister, Abraham Weintraub, has been fined R$ 2,000 for attending a pro-Bolsonaro protest without wearing a mask, thus violating local Distrito Federal rules, and is rumored to be relieved from his office, especially after president Jair Bolsonaro said he “was not prudent”. The Brazilian Ministry of Health has officially allowed openly homosexual men to donate their blood, putting an end to a long-standing discrimination. Authorities from the southern city of Porto Alegre, capital of Rio Grande do Sul, have issued a decree shutting down shopping malls and other commercial establishments, after registering a surge in the number of people infected by the novel coronavirus. Finally, on the same day the United States Food and Drug Administration issued an official revocation of its previous authorization for an emergency-use of chloroquine to treat COVID-19, Brazil decided to allow pregnant women and children to use the drug. Take a look at our highlights.. Texto em inglês com áudio da Gazeta do Povo.
- 06/16/2020
|
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Acorda Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
- NEW YORK, NY / ACCESSWIRE / June 16, 2020 / Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
- 06/16/2020
|
FDA revokes authorisation for Trump-approved malaria drug
- The United States Food and Drug Administration will revoke its emergency authorisation of anti-malaria drug hydroxychloroquine after finding it ineffective in treating COVID-19. The FDA said "in light of serious side affects - such as heart problems - the potential benefits from treatment no longer outweigh the risks". The emergency authorisation was issued in March,…
- 06/16/2020
|
FDA Withdraws Emergency Use Authorization For Hydroxychloroquine
- The United States Food and Drug Administration on Monday withdrew the emergency use authorization it granted for hydroxychloroquine and chloroquine sulfates against the COVID-19...
- 06/16/2020
|
'It may not be effective for COVID-19' - FDA withdraws approval for chloroquine - TheCable
- The United States Foo stration (FDA) says it is withdrawing its approval for the emergency use of two anti-malaria drugs the treatment of COVID-19
- 06/15/2020
|
Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region
- Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply, it added.
- 06/15/2020
|
Sun Pharma, Hikma ink exclusive pact for plaque psoriasis drug for MENA region
- Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in all MENA markets and Sun Pharma will be responsible for product supply, it added.
- 06/15/2020
|
Abiomed Appoints New Chief Medical Officer Charles Simonton, M.D.
- Abiomed (Nasdaq: ABMD), maker of the Impella heart pump, announced today it has appointed Charles (Chuck) Simonton, M.D., as vice president and chief
- 06/15/2020
|
CBA appoints Simon Moutter to board: Aus shares to open higher
- 15 Jun 2020 - The Australian share market is set to open higher this morning after Wall Street rebounded on Friday. Technology and financial stocks led the recovery. Coronavirus developments will be front and centre this week, with a raft of economic news on the agenda. The Commonwealth Bank of Australia (ASX:CBA) has appointed Simon Moutter as an Independent, Non-Executive Director.
- 06/14/2020
|
Grupo ignora decreto e protesta a favor de Bolsonaro na Esplanada
|
Revised Covid treatment protocol includes remdesivir, lists loss of smell as symptom of disease
- Apex health bodies across the world, including the Centers for Disease Control and Prevention, have in the last couple of months included loss of smell among the list of COVID symptoms.
- 06/14/2020
|
Remdesivir rollout to take more time as pharma firms working on providing safety, quality data
- India's drug regulator had on June 1 granted US pharma giant Gilead Sciences marketing authorisation for its drug remdesivir, being touted as a potential treatment for COVID-19, in the country.
- 06/13/2020
|
Anti-coronavirus drug remdesivir rollout to take time as pharma firms focus on quality
- The rollout of anti-coronavirus drug, remdesivir will take more time as pharmaceutical firms are working on providing safety and quality data for its production. The Union Health Ministry has recommended the use of remdesivir under emergency use authorization on patients with moderate disease.
- 06/13/2020
|
Potential COVID-19 drug: Zydus Cadila inks licensing pact with Gilead for remdesivir
- Remdesivir, the investigational drug from Gilead Sciences Inc, has been issued an 'emergency use authorisation' (EUA) by the United States Food and Drug Administration (USFDA) to treat patients suffering from severe symptoms of coronavirus, Zydus Cadila said in a statement.
- 06/12/2020
|
Zydus Cadila inks licensing pact with Gilead for remdesivir
- Drug firm Zydus Cadila on Friday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of remdesivir, a potential therapy for COVID-19.
- 06/12/2020
|
Teladoc (TDOC) Soars 193% in a Year: What's Behind the Rally?
- Teladoc (TDOC) continues to benefit from constant top-line growth and strategic initiatives, which have been aiding its share price.
- 06/12/2020
|
Remdesivir, tocilizumab being considered for ‘restricted use’ on severely ill COVID-19 patients
- The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol, sources in the know of the developments told PTI.
- 06/11/2020
|
Remdesivir, tocilizumab being considered for 'restricted use' on severely ill COVID-19 patients
- Anti-viral drug remdesivir and tocilizumab, an immunomodulator, are being considered for 'restricted use' on severely ill COVID-19 patients on 'emergency and compassionate grounds', according to revised clinical management guidelines to be released soon.
- 06/11/2020
|
Remdesivir being considered for 'restricted use' on severely ill covid patients
- The much-touted anti-malarial drug hydroxychloroquine will continue to be used while azythromycin may be dropped from the treatment protocol
- 06/11/2020
|
Is the Options Market Predicting a Spike in Acorda Therapeutics (ACOR) Stock?
- Investors need to pay close attention to Acorda Therapeutics (ACOR) stock based on the movements in the options market lately.
- 06/09/2020
|
Shares of several healthcare companies are trading higher on continued optimism amid the reopening of the economy, which would increase consumer spending and economic activity.
|
Maharashtra to procure 10,000 vials of Remdesivir drug, says Minister Rajesh Tope
- Maharashtra Health Minister Rajesh Tope on Saturday said that the state will procure 10,000 vials of Remdesivir drug.
- 06/06/2020
|
FDA Approves Abiomed’s First-in-Human Trial of Impella ECP, World’s Smallest Heart Pump
- Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption appl
- 06/05/2020
|
Acorda (ACOR) Down 11.8% Since Last Earnings Report: Can It Rebound?
- Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- 06/04/2020
|
COVID-19: Pharma giants seek DCGI's approval to manufacture, sell Remdesivir drug
- Two domestic pharmaceutical firms--Mylan and Jubilant Life Sciences have approached the country's top drug regulator--Drug Controller General of India (DCGI) to seek its approval to manufacture and sell anti-viral drug 'Remdesivir' in India to combat COVID-19.
- 06/04/2020
|
COVID-19 Therapeutics: The Leading Contenders
- While there is a huge interest in Covid-19 vaccine candidates, therapeutics are also an immediate need and will still be greatly in demand even after vaccines a
- 06/04/2020
|
Acadia Healthcare Ties Up for Improved Behavioral Services
- Acadia Healthcare (ACHC) partners with Covenant Health for offering improved mental health services in East Tennessee.
- 06/03/2020
|
India's drug regulator grants Gilead Sciences marketing authorization for remdesivir
- Read more about India's drug regulator grants Gilead Sciences marketing authorization for remdesivir on Devdiscourse
- 06/02/2020
|
COVID-19: India’s drug regulator grants Gilead Sciences marketing authorisation for remdesivir
- An earlier study results showed that when treating patients with severe disease - those who require non-invasive supplemental oxygen - 5 days of remdesivir led to similar improvements as a 10-day course.
- 06/02/2020
|
Novacyt shares drop as France refuses to refund virus test
- Read more about Novacyt shares drop as France refuses to refund virus test on Devdiscourse
- 06/02/2020
|
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir
- Read more about India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir on Devdiscourse
- 06/02/2020
|
Strides Pharma gets USFDA nod for generic ointment to treat skin conditions
- Read more about Strides Pharma gets USFDA nod for generic ointment to treat skin conditions on Devdiscourse
- 06/02/2020
|
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir
- India's drug regulator has granted US pharma giant Gilead Sciences marketing authorisation for its anti-viral drug remdesivir for "restricted emergency use" on hospitalised COVID-19 patients.
- 06/02/2020
|
Sensex, Nifty close nearly 2% higher, shrug Moody’s downgrade
- Sensex advanced 522 points or 1.6% to close at 33,825. Nifty climbed 153 points or 1.6% to end at 9,979.Bajaj Finance, Kotak Bank and IndusInd Bank, surging 6-8% were top Sensex gainers
- 06/02/2020
|
India's drug regulator grants Gilead Sciences marketing authorisation for remdesivir
- India's drug regulator has granted US pharma giant Gilead Sciences marketing authorisation for its anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients in view of the crisis posed by the pandemic.
- 06/02/2020
|
India's drug regulator grants Gilead Sciences marketing authorization for remdesivir
- Read more about India's drug regulator grants Gilead Sciences marketing authorization for remdesivir on Devdiscourse
- 06/01/2020
|
FDA Issues Emergency Use Authorization for Impella RP as Therapy for COVID-19 Patients with Right Heart Failure
- The United States Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) for Impella RP to include patients suffering from
- 06/01/2020
|
Hikma Pharmaceuticals : USA launches Dicyclomine Hydrochloride Oral Solution USP in US | MarketScreener
|
INSIDE STORY: How Kogi is turning a blind eye to patients with COVID-19 symptoms - TheCable
- It was scorching hot on Saturday afternoon in Lokoja, Kogi, when Godwin (not real name) managed to drag himself to one of the hospitals in th
- 05/28/2020
|
Biocon gets DCGI nod for device to treat critical COVID-19 patients
- The company has been granted licence for emergency use of CytoSorb, an extracorporeal blood purification device CytoSorb to reduce pro-inflammatory cytokines levels, to treat COVID-19 patients who are 18 years of age or older.
- 05/27/2020
|
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancin
- 05/26/2020
|
Germany Respiratory Devices Market 2019-2025 - ResearchAndMarkets.com
|
Coronavirus (Covid-19) Vaccine Latest Update: Oxford’s trial on rhesus macaques shows promise; tobacco-based jab ready for human tests
- Coronavirus (Covid-19) Vaccine Latest Update: From Oxford University's coronavirus vaccine trial on rhesus macaque monkeys showing promise to a vaccine made with proteins from tobacco leaves ready for human tests, the challenge to develop an injection has only intensified.
- 05/18/2020
|
Mesoblast Stock Soars on Promise of Cellular Medicine
- Longevity is potentially a trillion-dollar industry - until it isn't, because we can't keep the vulnerable safe from the latest pandemic. The Woohoo Flu has us distracted from the longevity thesis for a bit as the medical community scrambles to deal with something we can't control. A lack of information and a fractured population means it's also becoming political. At least we should all be grateful the overall mortality rates are low or we'd be royally screwed. Eventually, humankind will sort this out just like every other challenge we've been given, and we'll all get back to being excited about
- 05/17/2020
|
Top cigarette maker develops novel coronavirus vaccine, claims it is ready for human trials
- The word's No. 2 cigarette company claims it has developed an experimental vaccine for the novel coronavirus that has shown promise in laboratory testing and is now ready to be experimented on humans
- 05/15/2020
|
Sensex, Nifty slip further; pharma shares decline
- The market barometers slipped further in mid-morning trade, extending yesterday's steep losses. At 11:25 IST, the barometer index, the S&P BSE Sensex, was down 303.02 points or 0.97% at 30,819.87. The Nifty 50 index was down 78.75 points or 0.86%
- 05/15/2020
|
Unichem Laboratories jumps 10% on getting EIR from USFDA for Roha facility
- Unichem Lab stock had hit a 52-week high of Rs 200.60 on the BSE on May 24, 2019, while its 52-week low was Rs 75.10, hit on March 23 this year.
- 05/15/2020
|
Unichem Labs jumps on EIR from USFDA
- Unichem Laboratories surged 7.89% to Rs 137.50 after the company received the establishment inspection report (EIR) from the USFDA for its facility at Roha, Maharashtra.
- 05/15/2020
|
MARKET WRAP: Indices end flat, Sensex slips 25 pts; financials, autos fall
- All that happened in the markets today
- 05/15/2020
|
20 Healthcare Stocks Moving In Thursday's Pre-Market Session
|
Lupin gains 3% as Vizag API facility receives EIR from USFDA
- Brokerage firm Prabhudas Lilladher has upgraded Lupin's stock to 'Buy' from earlier 'Reduce' with target price of Rs 978
- 05/14/2020
|
Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data an
- 05/14/2020
|
Ottawa seeks information from suppliers on availability of fentanyl as demand increases
- André Gagnon, a spokesman for Health Canada, said the department has been looking at the Canadian supply chain to identify areas where supply may be vulnerable, and addressing any weaknesses before shortages occur
- 05/13/2020
|
TREVI THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) | MarketScreener
|
Sesen Bio Reports Positive Interactions with EMA on Regulatory Pathway for Vicinium®
- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, tod
- 05/07/2020
|
DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600
- S&P; Dow Jones Indices will make the following changes to the S&P; 500, S&P; 100, S&P; MidCap 400, and S&P; SmallCap 600 effective prior to the opening on Tuesday, May 12:
- 05/06/2020
|
Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
- Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.
- 05/06/2020
|
ALNYLAM PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q) | MarketScreener
|
H.C. Wainwright Reiterates Neutral on Acorda Therapeutics, Lowers Price Target to $5
|
Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y
|
Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates
- Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/05/2020
|
Acorda Therapeutics Q1 EPS $(0.510) Misses $(0.350) Estimate, Sales $28.099M Miss $41.010M Estimate
|
Acorda Reports First Quarter 2020 Financial Results and Provides Business Update
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
20 Healthcare Stocks Moving In Monday's Pre-Market Session
|
30 Stocks Moving in Monday's Pre-Market Session
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Acorda Therapeutics Inc (NASDAQ:ACOR) Shares Acquired by Bank of America Corp DE
- Bank of America Corp DE lifted its stake in shares of Acorda Therapeutics Inc (NASDAQ:ACOR) by 306.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 149,337 shares of the biopharmaceutical company’s stock after buying an additional 112,599 shares during the quarter. Bank of […]
- 05/02/2020
|
Personal de limpieza se arriesga para trabajar en pandemia
- Lissette Serrano pidió una mascarilla cuando trabajaba limpiando inodoros y recogiendo basura en unas transitadas instalaciones para descansar en una autopista en Connecticut. Le dijeron que no había. Poco después presentó los síntomas del coronavirus y una enfermera le dijo que se aislara 14 días. Cuando le contó a su jefa que no podía salir de casa fue despedida, dijo Serrano. “Había dicho, ‘Eso es sólo una excusa, no quieres ir a trabajar’”, dijo la mujer de 49 años de su empleadora, por medio de un intérprete. “Esto no es una excusa”. Serrano es una de los aproximadamente 3.000 trabajadores de limpieza en el Hudson Valley de Nueva York y el condado Fairfield de Connecticut que pertenecen al Sindicato Internacional de Empleados de Servicio (SEIU, por sus siglas en inglés), ganan poco más de 16 dólares la hora y, en los últimos dos meses, han corrido riesgos para desinfectar oficinas, estaciones de tren y otras áreas públicas con poco equipo protector, dijo Alberto Bernandez, un líder sindical de distrito. Muchos, como Serrano, perdieron sus empleos cuando los edificios cerraron o cuando se vieron obligados a quedarse en casa porque tenían síntomas de la enfermedad COVID-19, agregó. Aproximadamente 80% del personal del limpieza es inmigrante, la mayoría hispano. Muchos no pueden acceder a subsidios por desempleo, a pesar de que pagan impuestos, porque viven en el país sin permiso legal. “En estos momentos la gente está teniendo que escoger entre alimentarse a ellos y a su familia o ir a trabajar enfermos y poner su vida en peligro y a otros en riesgo”, dijo. El esposo de Serrano todavía trabaja en una fábrica de cajas, pero necesitan el sueldo del empleo de ella para ayudarse a pagar las facturas y cuidar a su hija de 12...
- 05/01/2020
|
Cleaners risk health to work during coronavirus pandemic, then lose jobs
- Lissette Serrano is one of about 3,000 cleaners in New York’s Hudson Valley and Connecticut’s Fairfield County put themselves in harm’s way to disinfect public areas with little protective equipment.
- 05/01/2020
|
Cleaners risk health to work during pandemic, then lose jobs
- Many cleaners of businesses in the New York area have lost their jobs because buildings have shut or because they refuse to work after getting coronavirus symptoms while on the job
- 05/01/2020
|
Cleaners risk health to work during pandemic, then lose jobs
- Lissette Serrano asked for a mask while she did her job cleaning toilets and picking up trash at a busy rest stop on a Connecticut parkway. She was told there were none. Soon after, Serrano came down with coronavirus symptoms and was told by a nurse to isolate for 14 days. When she told her boss she could not leave home, Serrano said, she was fired. “She had said, ’That’s just an excuse, you don’t want to go to work,” the 49-year-old Serrano, speaking through a translator, said in Spanish of her employer. “This is not an excuse.” Serrano is one of about 3,000 cleaners in New York’s Hudson Valley and Connecticut’s Fairfield County who belong to the Service Employees International Union, make just over $16 an hour and in the past couple of months put themselves in harm’s way to disinfect offices, train stations and other public areas with little protective equipment, said Alberto Bernardez, a union district leader. Many, like Serrano, lost their jobs when buildings closed or when they were forced to stay home with COVID-19 symptoms, he said. About 80% of the cleaners are immigrants, mostly Hispanic. Many cannot access unemployment benefits, even though they pay taxes, because they are living in the country without legal permission. “Right now people are having to choose between feeding themselves and their family or going to work sick and putting their lives in jeopardy and putting others at risk,” he said. Serrano’s husband is still working at a box factory, but they need the money from her job to help pay the bills and take care of her 12-year-old daughter. She’s not sure what they will do now. “I’m so scared,” she said. So is Janeth Baldeon, a 35-year-old janitorial worker who lives in White Plains, New York, with her father and her...
- 05/01/2020
|
Cleaners risk health to work during pandemic, then lose jobs
- Lissette Serrano asked for a mask while she did her job cleaning toilets and picking up trash at a busy rest stop on a Connecticut parkway. When she told her boss she could not leave home, Serrano said, she was fired. “She had said, ’That’s just an excuse, you don’t want to go to work,” the 49-year-old
- 05/01/2020
|
Risau vaksin masih tiada, ini 3 ubat sedia ada terbaik berpotensi rawat Covid-19
- Ubat malaria, chloroquine atau hydroxychloroquine- berpotensi jadi ubat terbaik rawat Covid-19.
- 04/30/2020
|
The Michael J. Fox Foundation Releases New Video Resource to Empower Patients and Families to Participate in Critical Parkinson's Research
- The Michael J. Fox Foundation for Parkinson's Research (MJFF) has released a new video, "Together, We Can Solve the Parkinson's Puzzle," to illustrate the role each individual within a family and community can play to help scientists piece together a fuller picture of Parkinson'
- 04/29/2020
|
Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs
- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs. Dr. Walter will provide oversight for all U.S.
- 04/28/2020
|
Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020
- Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET.
- 04/28/2020
|
Contrasting Atara Biotherapeutics (NASDAQ:ATRA) & Acorda Therapeutics (NASDAQ:ACOR)
- Atara Biotherapeutics (NASDAQ:ATRA) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership. Earnings & Valuation This table compares Atara Biotherapeutics and Acorda Therapeutics’ revenue, earnings per share […]
- 04/28/2020
|
BioCryst Pharmaceuticals (NASDAQ:BCRX) vs. Acorda Therapeutics (NASDAQ:ACOR) Critical Survey
- BioCryst Pharmaceuticals (NASDAQ:BCRX) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, risk and valuation. Analyst Recommendations This is a summary of recent ratings and price targets for BioCryst Pharmaceuticals […]
- 04/26/2020
|
Bank of New York Mellon Corp Has $1.10 Million Position in Acorda Therapeutics Inc (NASDAQ:ACOR)
- Bank of New York Mellon Corp lessened its position in Acorda Therapeutics Inc (NASDAQ:ACOR) by 38.6% in the fourth quarter, Holdings Channel.com reports. The firm owned 541,307 shares of the biopharmaceutical company’s stock after selling 340,998 shares during the quarter. Bank of New York Mellon Corp’s holdings in Acorda Therapeutics were worth $1,104,000 at the […]
- 04/25/2020
|
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
- During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
- 04/24/2020
|
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
- During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.
- 04/24/2020
|
Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?
|
Sports Figures and Life Sciences Industry Leaders Team Up for "Stay Safe. Stay Together. Stay Healthy." Social Media Campaign to Help During COVID-19 Pandemic
- Russo Partners' Sports-Health Alliance, part of the New York City-based healthcare and technology communications firm, has launched "Stay Safe. Stay Together. Stay Healthy," a social media campaign to encourage individuals to reconnect, rebuild and strengthen personal relationships despite
- 04/23/2020
|
US Sleep-Wake Disorder Market (2019 to 2025) - Featuring Aeroflow, Arena Pharmaceuticals & Acorda Therapeutics Among Others
- Dublin, April 23, 2020 -- The "US Sleep-Wake Disorder Market 2019-2025" report has been added to ResearchAndMarkets.com's offering. The US sleep-wake.
- 04/23/2020
|
Multiple Sclerosis Drugs Industry Assessment 2020: Immunomodulators, Immunosuppressants, Interferons and Others
- The "Multiple Sclerosis Drugs Market Global Report 2020" report has been added to ResearchAndMarkets.com's offering.
- 04/21/2020
|
European Respiratory Devices Market 2020 by Product, End-user and Region - ResearchAndMarkets.com
- Press release content from Business Wire. The AP news staff was not involved in its creation.
- 04/21/2020
|
Global Multiple Sclerosis Drugs Market Study, 2020 - Leading Players are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Merck & Co, Sanofi, Teva Pharma, GlaxoSmithKline and Acorda Therapeutics - ResearchAndMarkets.com
|
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
- Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
- 04/16/2020
|
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
- Acorda Therapeutics (ACOR) closed the most recent trading day at $1.06, making no change from the previous trading session.
- 04/16/2020
|
Solid Biosciences Announces Appointment of Ian F. Smith to its Board of Directors
- Solid Biosciences Inc. (SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of Ian F. Smith to its board of directors effective April 15, 2020. Mr. Smith is a highly accomplished life sciences executive with more than
- 04/16/2020
|
Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know
|
Tech sector boosts the market: ASX closed 1.9% higher
- 14 Apr 2020 - It has been a mostly positive day of trade for the ASX after a small dip in early morning trade the local bourse managed to close 1.9% higher. As for the sectors today Infotech led the day and REITs the only sector to end the day lower. Centuria Industrial REIT (ASX:CIP) has completed a $130 million institutional placement.
- 04/14/2020
|
USFDA grants fee waiver to Cyclopharm (ASX:CYC) for Technegas application
- 14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $2.9 million related to its recently submitted New Drug Application (NDA) for Technegas.
- 04/14/2020
|
$39.34 Million in Sales Expected for Acorda Therapeutics Inc (NASDAQ:ACOR) This Quarter
- Analysts expect that Acorda Therapeutics Inc (NASDAQ:ACOR) will post $39.34 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Acorda Therapeutics’ earnings, with the lowest sales estimate coming in at $32.00 million and the highest estimate coming in at $42.80 million. Acorda Therapeutics posted sales of […]
- 04/12/2020
|
Mesoblast (ASX:MSB) see trials for COVID-19 lung distress
- 09 Apr 2020 - Mesoblast (ASX:MSB) today announced that its stem cell product candidate remestemcel-L will be formally evaluated in a randomized, placebo-controlled trial in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus infection (COVID-19).
- 04/09/2020
|
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
- The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
- 04/08/2020
|
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
- The FDA bestows a fast track status on Immunomedics' (IMMU) sacituzumab govitecan for treating adult patients with locally advanced or metastatic urothelial cancer (mUC).
- 04/08/2020
|
Immunomedics' Sacituzumab Govitecan Gets Fast Track Tag for UC
|
Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
- Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.
- 04/07/2020
|
Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
- Acorda Therapeutics (ACOR) closed the most recent trading day at $0.93, moving -0.11% from the previous trading session.
- 04/07/2020
|
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
- Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
- 04/07/2020
|
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
- Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
- 04/07/2020
|
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
- Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
- 04/07/2020
|
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
- Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
- 04/07/2020
|
Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know
|
